PureTech Health plc (LON:PRTC – Get Free Report) shares were up 6.3% on Tuesday . The company traded as high as GBX 127 ($1.68) and last traded at GBX 125.40 ($1.66). Approximately 1,234,305 shares changed hands during trading, an increase of 17% from the average daily volume of 1,059,029 shares. The stock had previously closed at GBX 118 ($1.56).
PureTech Health Stock Performance
The company has a market cap of £367.67 million, a PE ratio of -5.02 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The firm’s 50 day moving average is GBX 133.90 and its 200-day moving average is GBX 147.53.
About PureTech Health
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
See Also
- Five stocks we like better than PureTech Health
- Stock Market Sectors: What Are They and How Many Are There?
- Viking Therapeutics Stock Pops But Struggles to Hold Gains
- 3 REITs to Buy and Hold for the Long Term
- Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited
- Health Care Stocks Explained: Why You Might Want to Invest
- Meta Stock Holds Upside Potential as Analysts Cut Price Targets
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
